Iantrek has announced a controlled release plan for AlloSpan Canal, a novel platform designed to restore and maintain Schlemm’s canal. The system combines nitinol-guided canaloplasty with a biologic scaffold derived from homologous tissue, providing durable canal support without permanent synthetic implants.

AlloSpan Canal represents a next-generation approach to trabecular intervention, addressing the historical tradeoff between transient canaloplasty procedures and permanent hardware. The technology allows surgeons to expand the canal while reinforcing its structure with naturally derived tissue. It is aligned with an established procedural code for homologous tissue use (CPT 66175), the company said in a press release.

Following first-in-human cases outside the United States, Iantrek is initiating a controlled early access program at select US sites. The program will gather real-world data to support procedural refinement and surgeon experience ahead of a planned broader commercialization in 2027.

AlloSpan Canal represents an expansion of Iantrek’s Allo platform, which targets natural outflow restoration through biologic reinforcement. The AlloSert Uveo delivery system is a biointerventional surgical platform to enhance aqueous outflow via the uveoscleral pathway by reinforcing a controlled cyclodialysis cleft with a biologic scaffold. It was commercially launched in the United States in October 2025. With the AlloSpan Canal, these represent complementary surgical solutions that target both natural outflow pathways, enabling a comprehensive and physiologic approach to glaucoma intervention.

Sean Ianchulev, MD, MPH, professor of ophthalmology at New York Eye and Ear and founder of Iantrek, will discuss the technology during the 2026 Kelman Innovation Lecture at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting April 12 in Washington, DC.